In IDH1/2-mutated tumors such as gliomas, aberrant conversion of α-KG to the oncometabolite 2-hydroxyglutarate consumes NADPH and disrupts the cellular redox balance, increasing the susceptibility of cells to oxidative damage (47, 48). Here, IDH1 is linked to central nervous system cancer.